1,920 research outputs found
Minor rural building heritage and territorial features in local action group sud est barese area (Southern Italy)
In Apulia, minor rural buildings are normally affected by intense forms of abandonment and decay. These minor constructions are often reused in ways that are not in line with both their own characteristics and the territorial context that encloses them. These forms of deterioration often lead to disappearance of this heritage. This study is focused on the analysis of the minor rural building heritage and its relationship with the actual territory context of the Local Action Group Sud Est Barese (LAG SEB), made up of nine municipalities. The official cartography of Military Geographic Institute (IGM, 1:25 000), the Regional Technical Map (CTR, 1:5 000), the Informative Territorial System (SIT Puglia) database, and the Geographic Information System (GIS) software ArcMap ArcGis 10.5 were used in order to constitute the base cartography. To obtain information about localization of the rural buildings, IGM cartography has been used due to the greater number of contents related to the classification of buildings. Successively, the overlapping of IGM and CTR map data and the comparison of them with the digital orthophoto were useful to verify whether the buildings listed on IGM cartography still exist. All main territorial features were analyzed using datasets obtained from IGM, CTR and SIT Puglia databases. This work allowed to investigate the possible relationships between the typology and the distribution of minor rural buildings and the major territorial characteristics, such as land use, road network, orography, and karst formations. It was highlighted that, although all nine municipalities examined fall under the same LAG, these are very different from the point of view of territorial peculiarities and the use and enhancement of resources. Rural buildings in their territorial context near the coast show more diversified potentials, as these areas include different realities (urban centers, tourist and seasonal residential areas, production areas, etc.), while the innermost buildings are located in municipalities with a predominantly productive destination. The obtained results represent useful information to outline intervention policies, the implementation of which would serve to attempt to recover the building structures, or improve the quality and way of using them
An Unexplained Case of Progressive Spastic Paraparesis in an Individual with Known DiGeorge Syndrome
DiGeorge syndrome (22q11.2 deletion) is associated with several neurologic disorders including structural abnormalities involving brain and spine, movement disorders, and epilepsy. Progressive spastic paraparesis has not been reported with DiGeorge syndrome. We report an individual in which DiGeorge syndrome was associated with progressive spastic paraparesis. This report extends the clinical phenotype of DiGeorge syndrome and presents the differential diagnosis of progressive spastic paraparesis in individuals with DiGeorge syndrome which provides insight into the clinical evaluation of such individuals
Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis
Adipose stromal cells (ASC) secrete various trophic factors that assist in the protection of neurons in a variety of neuronal death models. In this study, we tested the effects of human ASC conditional medium (ASC-CM) in human amyotrophic lateral sclerosis (ALS) transgenic mouse model expressing mutant superoxide dismutase (SOD1(G93A)). Treating symptomatic SOD1(G93A) mice with ASC-CM significantly increased post-onset survival time and lifespan. Moreover, SOD1(G93A) mice given ASC-CM treatment showed high motor neuron counts, less activation of microglia and astrocytes at an early symptomatic stage in the spinal cords under immunohistochemical analysis. SOD1(G93A) mice treated with ASC-CM for 7 days showed reduced levels of phosphorylated p38 (pp38) in the spinal cord, a mitogen-activated protein kinase that is involved in both inflammation and neuronal death. Additionally, the levels of α-II spectrin in spinal cords were also inhibited in SOD1(G93A) mice treated with ASC-CM for 3 days. Interestingly, nerve growth factor (NGF), a neurotrophic factor found in ASC-CM, played a significant role in the protection of neurodegeneration inSOD1(G93A) mouse. These results indicate that ASC-CM has the potential to develop into a novel and effective therapeutic treatment for ALS
Measurement of the cross-section and charge asymmetry of bosons produced in proton-proton collisions at TeV with the ATLAS detector
This paper presents measurements of the and cross-sections and the associated charge asymmetry as a
function of the absolute pseudorapidity of the decay muon. The data were
collected in proton--proton collisions at a centre-of-mass energy of 8 TeV with
the ATLAS experiment at the LHC and correspond to a total integrated luminosity
of 20.2~\mbox{fb^{-1}}. The precision of the cross-section measurements
varies between 0.8% to 1.5% as a function of the pseudorapidity, excluding the
1.9% uncertainty on the integrated luminosity. The charge asymmetry is measured
with an uncertainty between 0.002 and 0.003. The results are compared with
predictions based on next-to-next-to-leading-order calculations with various
parton distribution functions and have the sensitivity to discriminate between
them.Comment: 38 pages in total, author list starting page 22, 5 figures, 4 tables,
submitted to EPJC. All figures including auxiliary figures are available at
https://atlas.web.cern.ch/Atlas/GROUPS/PHYSICS/PAPERS/STDM-2017-13
Search for chargino-neutralino production with mass splittings near the electroweak scale in three-lepton final states in âs=13âTeV pp collisions with the ATLAS detector
A search for supersymmetry through the pair production of electroweakinos with mass splittings near the electroweak scale and decaying via on-shell W and Z bosons is presented for a three-lepton final state. The analyzed proton-proton collision data taken at a center-of-mass energy of âs=13ââTeV were collected between 2015 and 2018 by the ATLAS experiment at the Large Hadron Collider, corresponding to an integrated luminosity of 139ââfbâ1. A search, emulating the recursive jigsaw reconstruction technique with easily reproducible laboratory-frame variables, is performed. The two excesses observed in the 2015â2016 data recursive jigsaw analysis in the low-mass three-lepton phase space are reproduced. Results with the full data set are in agreement with the Standard Model expectations. They are interpreted to set exclusion limits at the 95% confidence level on simplified models of chargino-neutralino pair production for masses up to 345 GeV
Validation of the triple timed upâandâgo test in LambertâEaton myasthenia
Introduction
There are no validated, practical, and quantitative measures of disease severity in LambertâEaton myasthenia (LEM).
Methods
Data from the Effectiveness of 3,4âDiaminopyridine in LambertâEaton Myasthenic Syndrome (DAPPER) trial were analyzed to assess triple timed upâandâgo (3TUG) reproducibility and relationships between 3TUG times and other measures of LEM severity.
Results
The coverage probability technique showed â„0.90 probability for an acceptable 3TUG difference of â€0.2, indicating that it is reproducible in LEM patients. The correlation between 3TUG times and lower extremity function scores was significant in subjects who continued and in those who were withdrawn from 3,4âdiaminopyridine free base. Worsening patientâreported Weakness SelfâAssessment Scale and Investigator Assessment of Treatment Effect scores corresponded with prolongation of 3TUG times.
Discussion
The 3TUG is reproducible, demonstrates construct validity for assessment of lower extremity function in LEM patients, and correlates with changes in patient and physician assessments. These findings, along with prior reliability studies, indicate 3TUG is a valid measure of disease severity in LEM
3,4-Diaminopyridine Base Effectively Treats the Weakness of Lambert-Eaton Myasthenia
Introduction: 3,4-diaminopyridine has been used to treat Lambert Eaton myasthenia (LEM) for thirty years despite the lack of conclusive evidence of efficacy.
Methods: We conducted a randomized double-blind placebo-controlled withdrawal study in LEM patients who had been on stable regimens of 3,4-diaminopyridine base (3,4-DAP) forââ„â3 months. The primary efficacy endpoint was >30% deterioration in Triple Timed Up-and-Go (3TUG) times during tapered drug withdrawal. The secondary endpoint was self-assessment of LEMârelated weakness (W-SAS).
Results: 32 participants were randomized to continuous 3,4-DAP or placebo. None of the 14 receiving continuous 3,4-DAP had >30% deterioration in 3TUG time vs 72% of the 18 who tapered to placebo (p<0.0001). W-SAS similarly demonstrated an advantage for continuous treatment over placebo (p<0.0001). Need for rescue and adverse events were more common in the placebo group.
Discussion: This trial provides significant evidence of efficacy of 3,4-DAP in the maintenance of strength in LEM
- âŠ